शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
VALIANTORGBSEVALIANT ORGANICS LIMITED· Chemicals & PetrochemicalsHighNeutral
Announced Wed, 12 Aug, 2026 · 16:18 IST

Q1 FY27 results: PAT nearly triples, revenue up 13% YoY

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemRelated Party TransactionsResults View source PDFExplain this filing

VALIANTORG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+5.0%Reaction day
₹325.30
prior close
₹341.55
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+4.8% vs market
Specialty Chemicals peers, median of 92sector+0.0%+5.0% vs sector

On the reaction day the stock moved 4.8 pts more than Nifty Microcap 250 and 5.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.0
15m
+0.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+5.0+0.2+4.8+0.0+5.0
Next day
-0.2+0.2-0.5+0.1-0.3
2d
-5.2+0.4-5.6-0.7-4.5
3d
-4.6+0.7-5.3-0.6-4.0
4d
-2.9+0.1-3.0-1.1-1.8
5d
-4.4+0.7-5.1-0.4-4.0
1w
-9.0+1.2-10.2+0.1-9.1
15d
-2.8+0.7-3.6+1.7-4.5
1m
+19.3-1.2+20.5-1.8+21.1
2m
+38.9-1.1+40.1-1.6+40.6
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 92Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Valiant Organics Q1 FY27 standalone revenue grew to Rs 23,154 lakhs, up 13.3% YoY. Net profit surged to Rs 2,182 lakhs from Rs 758 lakhs, a 188% rise. EPS at Rs 7.79 vs Rs 2.71. Board re-appointed Managing Director for 3 years and plans to shift registered office to Tarapur, Boisar. Pharma division now reported as a separate segment alongside Specialty Chemicals.

Likely market impact

Strong profit growth from margin expansion. MD continuity confirmed. Office relocation and Pharma segment addition signal operational restructuring.